News | April 22, 2026
Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Its a major breakthrough for women’s ovarian cancer care in Europe
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Subscribe To Our Newsletter & Stay Updated
